Friday, 16 October 2026European Markets

NEW SOURCES ENERGY Stock Went Down By Over 17% So Far On Wednesday

Loading stream...

Recent market performance has shown a significant decline in the shares of New Sources Energy (NSE.AS). At 14:13 EST on Wednesday, NSE.AS's shares had fallen by 17.65% to EUR0.01. This marked the second consecutive session of losses for the company, having a slight negative impact on the broader AEX-Index which also fell 0.93% to EUR772.56.

Disappointing Performance of NSE.AS Stocks

Investors in NSE.A.S are facing a difficult situation as the stock is currently trading significantly below its 52-week high price of EUR0.07. The last closing price signaled a drastic drop of 75.38%, indicating an unsatisfactory performance.

About New Sources Energy

New Sources Energy N.V., based in Amersfoort, Netherlands, is devoted to developing and investing in renewable energy electricity generation projects. However, over the past year, the company's return on equity - a key measure of business profitability - stood at a disheartening negative 288.52% level.

Volatile Market Performance

Despite its persistent bearish trend, the company's share price volatility has shown betterment. Over the last week, month, and quarter, average intraday variances were positive 23.08%, negative 0.60%, and positive 11.97% respectively. However, trading volumes have disappointingly been low, with Wednesday being 51.97% lower than the average trading volume of 97,859.

Lagging Behind in Moving Averages

Moreover, New Sources Energy lags significantly in terms of its moving averages. The stock price remains notably below both its 50-day moving average of EUR0.02 and 200-day moving average of EUR0.05, further highlighting the company's declining performance and casting doubts about its potential for future success.

Due to the prevailing conditions, investors are advised to closely monitor these developments and make their investment decisions wisely.

More news about NEW SOURCES ENERGY (NSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com